Effects of Moracizine Combined with Metoprolol on Hemodynamic Indices of the Left Atrium and Quality of Life in Patients with Atrial Fibrillation.

IF 0.7 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart Surgery Forum Pub Date : 2023-10-07 DOI:10.59958/hsf.5683

Gongzhu Han, Ting Fu, Yichao Zhang

{"title":"Effects of Moracizine Combined with Metoprolol on Hemodynamic Indices of the Left Atrium and Quality of Life in Patients with Atrial Fibrillation.","authors":"Gongzhu Han, Ting Fu, Yichao Zhang","doi":"10.59958/hsf.5683","DOIUrl":null,"url":null,"abstract":"BACKGROUND Drugs are the first choice of treatment for atrial fibrillation (AF), but there is currently a lack of efficient drug treatment options. The aim of this study was to investigate a combination drug treatment plan which may serve as a reference for the treatment of AF. METHODS A total of 316 AF patients admitted to Jiaozhou Central Hospital in Qingdao from October 2020 to October 2022 were selected for this retrospective study. They were divided into a control group (CG, metoprolol, n = 156) and an observation group (OG, moracizine combined with metoprolol, n = 160) based on the treatment they received. The CG and OG groups were compared for clinical efficacy, occurrence of AF, cardiac output (CO), cardiac indexes (CI), stroke volume (SV), stroke indexes (SI) and improvement in QOL. RESULTS The OG had a better effective rate of treatment, higher levels of CO, CI, SV and SI, and higher QOL scores compared to the CG, as well as a lower AF recurrence rate and AF burden (all p < 0.05). CONCLUSION Moracizine combined with metoprolol is an effective treatment for AF patients. This drug combination was found to reduce the AF recurrence rate and burden in AF patients, and to improve their hemodynamic indices and QOL.","PeriodicalId":51056,"journal":{"name":"Heart Surgery Forum","volume":"26 5","pages":"E463-E469"},"PeriodicalIF":0.7000,"publicationDate":"2023-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart Surgery Forum","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.59958/hsf.5683","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUND Drugs are the first choice of treatment for atrial fibrillation (AF), but there is currently a lack of efficient drug treatment options. The aim of this study was to investigate a combination drug treatment plan which may serve as a reference for the treatment of AF. METHODS A total of 316 AF patients admitted to Jiaozhou Central Hospital in Qingdao from October 2020 to October 2022 were selected for this retrospective study. They were divided into a control group (CG, metoprolol, n = 156) and an observation group (OG, moracizine combined with metoprolol, n = 160) based on the treatment they received. The CG and OG groups were compared for clinical efficacy, occurrence of AF, cardiac output (CO), cardiac indexes (CI), stroke volume (SV), stroke indexes (SI) and improvement in QOL. RESULTS The OG had a better effective rate of treatment, higher levels of CO, CI, SV and SI, and higher QOL scores compared to the CG, as well as a lower AF recurrence rate and AF burden (all p < 0.05). CONCLUSION Moracizine combined with metoprolol is an effective treatment for AF patients. This drug combination was found to reduce the AF recurrence rate and burden in AF patients, and to improve their hemodynamic indices and QOL.

查看原文本刊更多论文

莫拉西嗪联合美托洛尔对心房颤动患者左心房血流动力学指标及生活质量的影响。

背景：药物是治疗心房颤动（AF）的首选药物，但目前缺乏有效的药物治疗方案。本研究的目的是探讨一种可作为AF治疗参考的联合药物治疗方案。方法：选择2020年10月至2022年10月在青岛胶州市中心医院住院的316名AF患者进行回顾性研究。根据他们接受的治疗，将他们分为对照组（CG，美托洛尔，n=156）和观察组（OG，莫拉西嗪联合美托洛尔（n=160））。比较CG组和OG组的临床疗效、房颤发生率、心输出量（CO）、心脏指数（CI）、卒中量（SV）、卒中指数（SI）和生活质量改善情况。结果：OG治疗房颤有效率较高，CO、CI、SV、SI水平较高，生活质量评分较高，房颤复发率和负担较低（均p<0.05）。该药物组合被发现可以降低房颤患者的房颤复发率和负担，并改善他们的血液动力学指标和生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Heart Surgery Forum 医学-外科

CiteScore

1.20

自引率

16.70%

发文量

130

审稿时长

6-12 weeks

期刊介绍： The Heart Surgery Forum® is an international peer-reviewed, open access journal seeking original investigative and clinical work on any subject germane to the science or practice of modern cardiac care. The HSF publishes original scientific reports, collective reviews, case reports, editorials, and letters to the editor. New manuscripts are reviewed by reviewers for originality, content, relevancy and adherence to scientific principles in a double-blind process. The HSF features a streamlined submission and peer review process with an anticipated completion time of 30 to 60 days from the date of receipt of the original manuscript. Authors are encouraged to submit full color images and video that will be included in the web version of the journal at no charge.